Two drugs have shown incredible weight loss and A1C reduction in phase 2 Trials. These are:
Retatrutide is a TriG agonist (GLP-1, GIP, and Glucagon). CagriSema is a combination of Semaglutide and Cagrilintide.
Cagrilinitide is a long-acting Amylin analog. Pramlintide is a short-acting amylin analog and has already been approved for the treatment of Type 1 Diabetes.
The weight loss effects of these two drugs range between 20 to 30%.